2016+专家意见书：心肌梗死后二级预防长期双抗治疗.pdf

review article Wien Klin Wochenschr DOI 10.1007/s00508-016-1016-7 Expertpositionpaperonprolongeddualantiplatelettherapy insecondarypreventionfollowingmyocardialinfarction Thomas W. Weiss ∙ Josef Aichinger ∙ Kurt Huber ∙ Walter S. Speidl ∙ Norbert Watzinger ∙ Robert Zweiker ∙ Hannes F. Alber Received: 22 April 2016/Accepted: 2 May 2016 © The Author(s) 2016. This article is available at SpringerLink with Open Access SummaryThe protective effect of dual antiplatelet therapy (DAPT) following acute coronary syndrome is undisputed, but its duration is subject of debate. Several studies show that prolonged therapy provides a clinical benefit in patients following acute coronary syndrome. The aim of this position paper authored by Austrian experts is to outline the current evidence and provide an overview of recent studies. It is also intended to serve as a practical guide to identify those patients who may benefit from prolonged DAPT. KeywordsP2Y 12inhibitor · Acute coronary syndrome · DAPT · Myocardial infarction · Ticagrelor T.W.Weiss,MD,PhD,FESC( fi) · K. Huber 3rd Medical Department of Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria e-mail: thomas.weiss@meduniwien.ac.at J. Aichinger Internal Department 2 – Cardiology, Angiology and Internal Intensive Medicine, Krankenhaus der Elisabethinen Linz, Linz, Austria W. S. Sp eid l Clinical Department of Cardiology, University Clinic of General Medicine II, Medical University of Vienna, Vienna, Austria N. Watzinger Department of General Medicine, Landeskrankenhaus Feldbach, Feldbach-Fürstenfeld Hospital Group, Feldbach, Austria R. Zweiker Department of Cardiology, Medical University of Graz, Graz, Austria H. F. Alber University Clinic of General Medicine III at the Medical University of Innsbruck, Reha-Zentrum Münster, Tyrol and Karl Landsteiner Institute for Interdisciplinary Research at the Reha-Zentrum Münster, Münster/Tyrol, Austria Introduction Platelet activation and aggregation with consecutiv